Banerjee, Rajat <br/><br/>
TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer.  [electronic resource] 

 -  Nature communications  Jul 2014 
 - 4527 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>2041-1723 
<br/><br/><label>Standard No.: </label>10.1038/ncomms5527  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>ATPases Associated with Diverse Cellular Activities<br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Carcinoma, Squamous Cell--drug therapy<br/>Carrier Proteins--antagonists & inhibitors<br/>Cell Cycle Proteins<br/>Cell Line, Transformed<br/>Cell Line, Tumor<br/>Cell Movement<br/>Cell Transformation, Neoplastic--genetics<br/>Chick Embryo<br/>Chorioallantoic Membrane--blood supply<br/>DNA Breaks, Double-Stranded<br/>DNA End-Joining Repair<br/>DNA-Activated Protein Kinase--antagonists & inhibitors<br/>Drug Resistance, Neoplasm--genetics<br/>Gene Expression Regulation, Neoplastic<br/>Head and Neck Neoplasms--drug therapy<br/>Humans<br/>Injections, Subcutaneous<br/>Keratinocytes--drug effects<br/>Mice<br/>Mice, Nude<br/>NIH 3T3 Cells<br/>Nuclear Proteins--antagonists & inhibitors<br/>RNA, Small Interfering--genetics<br/>Signal Transduction<br/>Squamous Cell Carcinoma of Head and Neck<br/>Xenograft Model Antitumor Assays